340 related articles for article (PubMed ID: 26597253)
1. The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.
Hibma JE; Zur AA; Castro RA; Wittwer MB; Keizer RJ; Yee SW; Goswami S; Stocker SL; Zhang X; Huang Y; Brett CM; Savic RM; Giacomini KM
Clin Pharmacokinet; 2016 Jun; 55(6):711-21. PubMed ID: 26597253
[TBL] [Abstract][Full Text] [Related]
2. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers.
Morrissey KM; Stocker SL; Chen EC; Castro RA; Brett CM; Giacomini KM
Clin Pharmacokinet; 2016 Apr; 55(4):495-506. PubMed ID: 26507723
[TBL] [Abstract][Full Text] [Related]
4. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
[TBL] [Abstract][Full Text] [Related]
5. The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects.
Ding Y; Jia Y; Song Y; Lu C; Li Y; Chen M; Wang M; Wen A
Eur J Clin Pharmacol; 2014 Feb; 70(2):141-6. PubMed ID: 24170325
[TBL] [Abstract][Full Text] [Related]
6. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Topletz-Erickson AR; Lee AJ; Mayor JG; Rustia EL; Abdulrasool LI; Wise AL; Dailey B; DeChenne S; Walker LN; Alley SC; Endres CJ
J Clin Pharmacol; 2021 Apr; 61(4):461-471. PubMed ID: 32989831
[TBL] [Abstract][Full Text] [Related]
7. Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.
Grün B; Kiessling MK; Burhenne J; Riedel KD; Weiss J; Rauch G; Haefeli WE; Czock D
Br J Clin Pharmacol; 2013 Nov; 76(5):787-96. PubMed ID: 23305245
[TBL] [Abstract][Full Text] [Related]
8. The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment.
Cho SK; Chung JY
Int J Clin Pharmacol Ther; 2016 Apr; 54(4):253-62. PubMed ID: 26784938
[TBL] [Abstract][Full Text] [Related]
9. The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers.
Liu G; Wen J; Guo D; Wang Z; Hu X; Tang J; Liu Z; Zhou H; Zhang W
J Pharmacol Sci; 2016 Dec; 132(4):244-248. PubMed ID: 27245553
[TBL] [Abstract][Full Text] [Related]
10. No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects.
Choi T; Komirenko AS; Riddle V; Kim A; Dhuria SV
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):818-826. PubMed ID: 30605260
[TBL] [Abstract][Full Text] [Related]
11. Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine.
Shi R; Xu Z; Xu X; Jin J; Zhao Y; Wang T; Li Y; Ma Y
Eur J Pharm Sci; 2019 Jan; 127():282-290. PubMed ID: 30428337
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycaemic activity in humans.
Oh J; Chung H; Park SI; Yi SJ; Jang K; Kim AH; Yoon J; Cho JY; Yoon SH; Jang IJ; Yu KS; Chung JY
Diabetes Obes Metab; 2016 Jan; 18(1):104-8. PubMed ID: 26381793
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine.
Elsby R; Chidlaw S; Outteridge S; Pickering S; Radcliffe A; Sullivan R; Jones H; Butler P
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971610
[TBL] [Abstract][Full Text] [Related]
14. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.
Stocker SL; Morrissey KM; Yee SW; Castro RA; Xu L; Dahlin A; Ramirez AH; Roden DM; Wilke RA; McCarty CA; Davis RL; Brett CM; Giacomini KM
Clin Pharmacol Ther; 2013 Feb; 93(2):186-94. PubMed ID: 23267855
[TBL] [Abstract][Full Text] [Related]
15. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin.
Tsuda M; Terada T; Mizuno T; Katsura T; Shimakura J; Inui K
Mol Pharmacol; 2009 Jun; 75(6):1280-6. PubMed ID: 19332510
[TBL] [Abstract][Full Text] [Related]
16. A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: An open-label, parallel group, randomized clinical study.
Chung H; Oh J; Yoon SH; Yu KS; Cho JY; Chung JY
PLoS One; 2018; 13(1):e0191258. PubMed ID: 29342199
[TBL] [Abstract][Full Text] [Related]
17. Co-administration of nuciferine reduces the concentration of metformin in liver via differential inhibition of hepatic drug transporter OCT1 and MATE1.
Li L; Lei H; Wang W; Du W; Yuan J; Tu M; Zhou H; Zeng S; Jiang H
Biopharm Drug Dispos; 2018 Nov; 39(9):411-419. PubMed ID: 30294927
[TBL] [Abstract][Full Text] [Related]
18. Impact of Direction of Transport on the Evaluation of Inhibition Potencies of Multidrug and Toxin Extrusion Protein 1 Inhibitors.
Saito A; Ishiguro N; Takatani M; Bister B; Kusuhara H
Drug Metab Dispos; 2021 Feb; 49(2):152-158. PubMed ID: 33262224
[TBL] [Abstract][Full Text] [Related]
19. A Drug-Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2- and MATE1-Mediated Transport of Metformin in Healthy Participants.
Bhardwaj R; Morris B; Matschke K; Bertz R; Croop R; Liu J
Clin Pharmacol Drug Dev; 2024 May; 13(5):465-473. PubMed ID: 38174905
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of metformin.
Graham GG; Punt J; Arora M; Day RO; Doogue MP; Duong JK; Furlong TJ; Greenfield JR; Greenup LC; Kirkpatrick CM; Ray JE; Timmins P; Williams KM
Clin Pharmacokinet; 2011 Feb; 50(2):81-98. PubMed ID: 21241070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
